Exane Derivatives Zymeworks Inc. Transaction History

Exane Derivatives

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 26, 2021	SELL	$27.35 - $37.28 $17,285 - $23,560	-632 Closed	0 $0
Q2 2021 Jul 28, 2021	SELL	$26.5 - $38.23 $123,384 - $177,998	-4,656 Reduced 88.05%	632 $21,000
Q1 2021 Apr 30, 2021	BUY	$29.83 - $56.81 $59,272 - $112,881	1,987 Added 60.19%	5,288 $166,000
Q4 2020 Jan 27, 2021	BUY	$39.12 - $54.99 $24,723 - $34,753	632 Added 23.68%	3,301 $156,000
Q3 2020 Oct 08, 2020	BUY	$29.21 - $46.58 $77,961 - $124,322	2,669 New	2,669 $124,000
Q3 2020 Oct 06, 2020	SELL	$29.21 - $46.58 $78,867 - $125,766	-2,700 Closed	0 $0
Q2 2020 Jul 10, 2020	BUY	$33.67 - $40.0 $90,909 - $108,000	2,700 New	2,700 $97,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $949M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.